A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Phase of Trial: Phase I/II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs TAK 754 (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Baxalta; Shire; Takeda
- 21 Nov 2019 Planned number of patients changed from 10 to 12.
- 21 Nov 2019 Planned End Date changed from 30 Jun 2022 to 30 May 2023.
- 21 Nov 2019 Planned primary completion date changed from 30 Jun 2022 to 30 May 2023.